Desaturations During 6-Minute Walk Test and Predicting Nocturnal Desaturations in Adult Subjects With Cystic Fibrosis

Rosa Mar Gómez Punter, Rosa M Girón Moreno, Emma Vázquez Espinosa, Joan B Soriano, M Teresa Pastor, Enrique Zamora, Claudia Valenzuela, Tamara Alonso, Elena García Castillo, and Julio Ancochea

BACKGROUND: Nocturnal desaturation in cystic fibrosis (CF) may have prognostic implications because a significant and maintained nocturnal desaturation can contribute to the development and progression of pulmonary hypertension with cor pulmonale. Its relation with the desaturation in exercise has not been sufficiently studied. We aimed to determine whether desaturation during 6MWT can be an indicator of nocturnal desaturation in adult subjects with CF. **METHODS:** 57 subjects were included: 50.9% male, 27.5 ± 7.7 y old, mean $FEV_1 = 2.37 \pm 0.74$ L, and $\%FEV_1 = 67 \pm 18.1\%$. Desaturation during 6MWT was defined as oxygen saturation (S_{pO_2}) $\leq 90\%$ or a decline of > 4 points in S_{pO_2} from baseline, and nocturnal desaturation as a desaturation index > 4 or $> 5\%$ of sleep time with $S_{pO_2} \leq 90\%$. **RESULTS:** Desaturation observed during 6MWT in adult subjects with CF did not correlate with nocturnal desaturation ($P = .27$). Subjects with $\%FEV_1 \leq 55\%$ and diffusion capacity of carbon monoxide (D_{LCO}) ≤ 50 mmol/min/mm Hg were at higher risk of 6MWT desaturation. Nocturnal desaturation was more frequent in males, with $P_{aO_2} \leq 71$ mm Hg in blood gas analysis. **CONCLUSIONS:** Desaturation observed in 6MWT cannot predict desaturation at night in adults with CF. Other parameters were identified as predictors of desaturation. *Key words:* saturation; walk; pulse oximetry; sleep; oxygen; exercise; hypoxemia. [Respir Care 2019;64(1):48–54. © 2019 Daedalus Enterprises]

Introduction

Cystic fibrosis (CF) is one of the most common genetic diseases in whites,^{1,2} with an incidence of about 1 in 5,000 live births in Spain.² It is an autosomal recessive inheritance disease that affects exocrine glands of different organs and systems, causing abnormal secretions that produce obstruction and favor infection. Just a few de-

cades ago, mortality in CF was high, with a median survival < 4 y. However, significant improvement in survival has been recently seen. In the United States in 2015, according to the Cystic Fibrosis Foundation, CF median survival was 41.6 y.³

In subjects with respiratory diseases, exercise tests have been extensively used to provide information about prognosis and disability, to determine the presence of exercise hypoxemia, and to assess response to treatment. Cardio-pulmonary exercise testing is used as a standard test, but it has many limitations due to technical complexity and costs; therefore, in recent years the 6-min walk test (6MWT) has been increasingly used. The 6MWT consists of measuring the maximum distance a person can walk in 6 min. This distance has been shown to indirectly predict morbidity and mortality.⁴

The clinical value of the 6MWT test in adults with CF has been insufficiently studied. Most available studies have been done in small groups or in assessments of lung transplantations. The work of Martin et al⁵ performed in adults with stable CF and varying degrees of pulmonary obstruc-

The authors are affiliated with the Servicio de Neumología. Instituto de Investigación Sanitaria Princesa (IISP), Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.

The authors have disclosed no conflicts of interest.

Supplementary material related to this paper is available at <http://www.rcjournal.com>.

Correspondence: Rosa Mar Gómez Punter, Servicio de Neumología. Hospital Universitario de la Princesa, C/Diego de León 62, 28006, Madrid, Spain. E-mail: rosamar_gp@hotmail.com.

DOI: 10.4187/respcare.06171

tion showed that a 6MWT distance ≤ 475 m or desaturation ($S_{pO_2} \leq 90\%$) during the test were associated with increased risk of lung transplantation or death without transplantation.

On the other hand, sleep studies show that hypoxemia and hypercapnia occur as a result of a reduction in respiratory activity and tidal volume and a loss of functional residual capacity, especially during rapid eye movement sleep.⁶ Decreased S_{pO_2} that occurs during sleep is more pronounced in patients with CF than in normal individuals. A significant and maintained nocturnal desaturation can contribute to a development and progression of pulmonary hypertension with cor pulmonale.⁶⁻⁸

CF guidelines recommend an annual exercise tolerance test or measurement of blood gases (eg, pulse oximetry, capnography, arterial blood gases).⁹ In patients presenting with an $FEV_1 \leq 50\%$ or with resting $S_{pO_2} = 93-94\%$, nocturnal pulse oximetry is recommended.⁹ There are few studies of subjects with CF where nocturnal desaturation were measured.⁸ Furthermore, there is no universally agreed definition of desaturation, which complicates standardization.

To date, available studies linking desaturation during sleep with that during exercise in subjects with CF have been mostly performed in children.^{10,11} To our knowledge, there are no reports exploring desaturation with 6MWT and nocturnal pulse oximetry in adults with CF.

We aimed to determine whether measurements of pulse oximetry desaturation during the 6MWT could be a good predictor of nocturnal desaturation in adult subjects with CF. Secondary objectives were to determine the relationships between 6MWT and nocturnal desaturation with lung function, quality of life measured by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), and body mass index (BMI).

Methods

We included subjects diagnosed with CF who were ≥ 18 y, followed up in a specialized CF unit in Madrid, Spain.^{12,13} Inclusion criteria were clinical stability during the previous 4 weeks (ie, no exacerbations requiring treatment modification or hospital admission), the ability to understand and comply with the procedures, and the ability to give informed consent. The research protocol was approved by the Ethics Committee, and all participants provided written informed consent. Exclusion criteria were patients requiring home oxygen therapy, patients with previous lung transplant and any motor neuromuscular disorder, and patients who could not perform the 6MWT in the opinion of the principal investigator.

Subjects were referred to the Functional Respiratory Exploration Laboratory, where both a baseline arterial blood gas analysis and 6MWT were performed. Later, in the sleep unit, subjects were given a pulse oximeter capable of storing S_{pO_2} data overnight.

QUICK LOOK

Current knowledge

The clinical value of the 6-min walk (6MWT) test in adults with cystic fibrosis has been insufficiently studied. Desaturations that occur during sleep are more pronounced in individuals with cystic fibrosis. A significant and maintained nocturnal desaturation can contribute to the development and progression of pulmonary hypertension with cor pulmonale.

What this paper contributes to our knowledge

We measured nocturnal desaturation via pulse oximetry and 6MWT desaturation in adult subjects with cystic fibrosis. Desaturation during 6MWT did not correlate with nocturnal desaturation in this population.

Collected clinical variables included sex, age, genetic mutation, pancreatic insufficiency, diabetes or glucose intolerance, impaired bone mineral density, occurrence of previous bronchial infection, and non-infectious respiratory complications (eg, massive hemoptysis, recurrent pneumothorax, atelectasis or allergic bronchopulmonary aspergillosis) and digestive complications. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m^2).¹⁴ Information about the number of exacerbations and treatment in the previous year, including the use of health care resources, were collected.

The Shwachman-Kulczycki,¹⁵ Brasfield,¹⁶ and modified Bhalla¹⁷ scores were used for the assessment of clinical status. Spirometry was performed using a spirometer (Vmax Sensormedics, CareFusion, San Diego, California). Collected data consisted of FVC in L and as a percentage compared to a theoretical value according to age, height, and sex; FEV_1 in L and as a percentage of its theoretical value, and the ratio FEV_1/FVC . In addition, we registered the results of the most recent plethysmography prior to the study and determination of diffusing capacity for carbon monoxide (D_{LCO}). The CFQ-R¹⁸ questionnaire was used for the assessment of quality of life in subjects with CF. The 6MWT was performed according to American Thoracic Society standards.¹⁹ We recorded distance walked, S_{pO_2} , and heart rate every minute and at the end of the test, along with dyspnea using the Borg scale at the beginning and end of testing. Our definition of desaturation during the 6MWT was a minimum $S_{pO_2} \leq 90\%$ or a drop of > 4 points between initial and final baseline S_{pO_2} .¹¹

Pulse oximetry (PulseOx-7500, SPO, Kfar Saba, Israel) was used with a digital sensor and a monitor, and the S_{pO_2} and heart rate were registered during the night. Variation in S_{pO_2} concentration was considered significant when oxygen desaturation was $\geq 4\%$ over baseline saturation. The

Fig. 1. Flow chart. ABG = arterial blood gas; 6MWT = 6-min walk test; CFQ-R = Cystic Fibrosis Questionnaire-Revised.

number of these events per hour in the registry is known as desaturation index. Desaturation in the sleep study was defined when the desaturation index was > 4 or when the sleep time with $S_{pO_2} \leq 90\%$ was $> 5\%$, as described elsewhere.²⁰⁻²³

We analyzed the relationships between nocturnal desaturation and 6MWT with regard to gender, age, mutations, and comorbidities.

Statistical Analysis

Given a type one error of 5%, with 19.3% of 6MWT desaturation and 57.9% of nocturnal desaturation, and the obtained sample size of 57 subjects, we determined that there was enough statistical power (99.6%) to detect significant changes. We compared categorical variables with chi-square tests. The Kolmogorov-Smirnov test was performed to check the normality of continuous variables. For normally distributed data, we compared means using parametric tests such as Pearson, Student *t*, and analysis of variance. For non-normally distributed data, we used non-parametric tests such as Spearman, Friedman, and Mann-Whitney depending on the variables. In the descriptive analysis, the results were expressed as mean $\pm$ SD for quantitative variables and as percentage for qualitative variables. Statistical significance was considered as $P < .05$. Results were analyzed with the statistical package SPSS version 15.0. (SPSS, Chicago, Illinois).

Results

Of 70 patients assessed for inclusion, 57 subjects were finally included. Thirteen patients were excluded: 3 subjects had home oxygen therapy, 2 were transplanted, and 8 declined to participate (Fig. 1). Males comprised 50.9% of the subjects, with a mean age of 27.5 ± 7.7 y and a mean of FEV₁ of 2.37 ± 0.74 L and %FEV₁ $67 \pm 18.1\%$.

Table 1. Demographic and Clinical Characteristics of Subjects

Characteristics	Mean $\pm$ SD	Range
Age, y	27.5 ± 7.7	18–54
Body mass index, kg/m ²	21.9 ± 2.9	16.8–31.4
Exacerbations in the previous year, no.	2.6 ± 1.7	0–7
Hospital admissions in the previous year, no.	0.4 ± 0.7	0–4
Shwachman-Kulczycki score ($n = 50$)	82.1 ± 11.9	53–100
Brasfield score ($n = 54$)	19.0 ± 3.9	10–25
Bhalla score ($n = 54$)	14.7 ± 3.8	9–25
FEV ₁ , L	2.37 ± 0.74	0.9–4.5
%FEV ₁	67.0 ± 18.1	30–108

Characteristics	Frequency, n (%)
Male	29 (50.9)
6MWT desaturation	11 (19.3)
Nocturnal desaturation	33 (57.9)
CFTR genotype	
F508del/F508del	20 (35.1)
F508del/unknown	14 (24.6)
F508del/other	12 (21.0)
Other/other	5 (8.7)
Other/unknown	3 (5.3)
Unknown/unknown	3 (5.3)

N = 57 subjects.

CFTR = cystic fibrosis transmembrane conductance regulator

Table 1 summarizes the demographic and clinical characteristics of the study subjects.

Although the total lung capacity of all subjects remained within normal limits, the existence of air trapping was confirmed in 75.4% of subjects. Moreover, 71.9% of the subjects had lung hyperinflation (functional residual capacity $> 120\%$). Only 47 (82.5%) subjects in the study consented to perform a baseline arterial gasometry before the 6MWT.

Fifty subjects (87.7%) completed the CFQ-R (see the supplementary materials at <http://www.rcjournal.com>), of whom 96% were of Spanish white origin, and 86% of the subjects had education levels higher than primary studies. The mean scores in the different sections of the CFQ-R ranged between 51.3 and 85.7, being lower in the sections of burden of treatment, weight loss, respiratory symptoms, and health perception scores.

In the 6MWT, minimum saturations were obtained without having to stop walking, with a low of 78% in some subjects. According to the definition of desaturation in the 6MWT, 11 subjects (19.3%) presented desaturation in the test, and 46 (80.7%) did not.

The mean time spent sleeping at night was 6 h and 13 min. The desaturation index was 6.4 ± 6.5 events per h, the minimum S_{pO_2} during sleep was $85.0 \pm 5.3\%$, and sleep time with $S_{pO_2} \leq 90\%$ was $13.7 \pm 26.7\%$. According

Table 2. Relationship Between Nocturnal Desaturation and 6MWT

	Nocturnal Desaturation			<i>P</i> = .27
	No	Yes	Total	
6MWT Desaturation				
No	21 (45.6)	25 (54.4)	46 (80.7)	
Yes	3 (23.3)	8 (72.7)	11 (19.3)	
Total	24 (42.1)	33 (57.9)	57 (100.0)	

Data are presented as *n* (%). Fig. 2. Minimum oxygen saturation (S_{pO_2}) during sleep and 6-min walk test (6MWT).

to the definition of desaturation during the sleep study, 33 subjects (57.9%) presented nocturnal desaturation measured by pulse oximetry, and 24 subjects did not (42.1%).

No relationship was observed between desaturation during the 6MWT and nocturnal desaturation ($P = .27$; P value relates patients with nocturnal desaturation and 6MWT desaturation) (Table 2). Therefore desaturation cannot be considered a predictor of response between these 2 phenomena. In 11 subjects with desaturation in the 6MWT, 8 (72.7%) had nocturnal desaturation versus 3 (27.3%) who did not. This was not a statistically significant difference. Only 14% of subjects presented desaturation in both tests (Table 2, Fig. 2). No association ($P = .30$) between the nocturnal desaturation measured by pulse oximetry with lung function (FEV_1 measured as a percentage of the theoretical value) was found. However, functional residual capacity was higher in subjects with desaturation statistically significant ($P = 0.05$) and also had higher RV (Table 3).

Of the 47 subjects who underwent blood gas analysis, 10 (21.2%) had desaturation in the 6MWT. The mean

baseline values of P_{aO_2} , P_{aCO_2} , and S_{aO_2} in subjects with and without desaturation are shown in Table 3. Moreover, 26 subjects (55.3%) presented with nocturnal desaturation. These subjects had higher mean levels of carbon dioxide and lower oxygen levels than those who did not desaturate. There were significant differences in the P_{aO_2} and P_{aCO_2} levels, but not in baseline S_{aO_2} ($P = .002$, $P = .01$, and $P = .055$, respectively) (Table 3).

The average score of the respiratory symptoms item in the CFQ-R in subjects with desaturation during the 6MWT was 64.2 ± 17.1 , which was slightly less than those who did not desaturate without reaching a significant difference ($P = .60$) (see the supplementary materials at <http://www.rcjournal.com>).

Neither nocturnal desaturation nor the respiratory domain of the CFQ-R were significantly related ($P = .37$). The average score that item was lower in subjects with nocturnal desaturation (64.7 ± 16.4) compared to other subjects (68.4 ± 16.8). A significant relationship with other items on the questionnaire were found as digestive ($P = .009$) and emotional ($P = .050$).

No association between BMI and 6MWT ($P = .24$) was identified, although the mean BMI of subjects with desaturation in the 6MWT (21.0 ± 3.1 kg/m²) tended to be lower than that of subjects who did not desaturate (22.1 ± 2.8 kg/m²).

There was no association between nocturnal desaturation and BMI ($P = .42$), and in this case the mean BMI of subjects with nocturnal desaturation (22.2 ± 3.2 kg/m²) was not significantly higher than the BMI of those who did not desaturate (21.6 ± 2.5 kg/m²).

Finally, there were statistically significant differences in the nocturnal desaturation by sex ($P = .02$); male subjects had higher nocturnal desaturation than female subjects (Table 4; P value relates nocturnal desaturation and male). We found no association of nocturnal desaturation with all other variables, such as the type of mutation, pancreatic insufficiency, or diabetes.

Discussion

We observed that desaturation during 6MWT in subjects with CF did not predict desaturation at night. However, subjects with $FEV_1 \leq 55\%$, $D_{LCO} \leq 50$ mmol/min/mm Hg, and baseline $S_{aO_2} \leq 94\%$ have a higher risk of desaturation in the 6MWT. Furthermore, being male with a $P_{aO_2} \leq 71$ mm Hg in arterial blood gas analysis increases the risk of nocturnal desaturation. We suggest that the lower frequency in nocturnal desaturation in women may be due to anatomical or hormonal factors.

Nocturnal pulse oximetry is a clinically useful test to detect hypoxemia during sleep, as shown in previous studies such as Montgomery et al,²² where it was reported that subjects with CF who had a P_{aO_2} concentration < 60 mm Hg

Table 3. Test Results for 6MWT Desaturation and Nocturnal Desaturation Groups

	6MWT Desaturation Group			Nocturnal Desaturation Group		
	No	Yes	P	No	Yes	P
Subjects, <i>n</i> (%)	46 (80.7%)	11 (19.3%)		24 (42.1%)	33 (57.9%)	
FEV ₁ , L	2.50 ± 0.71	1.82 ± 0.59	.004	2.31 ± 0.41	2.41 ± 0.90	.62
%FEV ₁	70.2 ± 15.4	53.3 ± 22.4	.004	69.8 ± 14.4	64.9 ± 20.3	.30
FVC, L	3.66 ± 0.86	2.91 ± 0.53	.001	3.36 ± 0.61	3.63 ± 0.99	.21
%FVC	83.5 ± 12.8	67.8 ± 13.0	.001	83.3 ± 11.8	78.4 ± 15.5	.20
FEV ₁ /FVC	68.8 ± 9.3	62.4 ± 16.1	.09	69.2 ± 9.8	66.3 ± 11.9	.35
TLC, L	5.77 ± 1.06	5.76 ± 1.01	.99	5.29 ± 0.94	6.10 ± 0.99	.057
%TLC	103.6 ± 12.3	107.8 ± 10.2	.35	104.5 ± 10.5	104.3 ± 13.1	.95
Residual volume/TLC	140.7 ± 35.3	164.2 ± 31.8	.07	133.6 ± 30.0	152.7 ± 37.4	.07
D _{LCO} , mmol/min/mm Hg	60 ± 12.75	50.25 ± 9.0	.041	57.75 ± 12.0	59.25 ± 13.5	.74
%D _{LCO}	81.2 ± 14.7	69.5 ± 10.4	.03	81.7 ± 13.1	77.4 ± 15.6	.31
Body mass index	22.15 ± 2.82	20.99 ± 3.11	.24	21.57 ± 2.49	22.19 ± 3.16	.43
Arterial blood gases, <i>n</i> (%)	37 (78.8%)	10 (21.2%)		21 (44.7%)	26 (55.3%)	
P _{O₂} , mm Hg	80.9 ± 10.2	74.0 ± 12.2	.08	84.7 ± 9.6	75.3 ± 10.2	.002
P _{CO₂} , mm Hg	35.5 ± 4.6	34.9 ± 3.7	.69	33.6 ± 3.7	36.8 ± 4.4	.01
S _{aO₂} , baseline (%)	95.5 ± 1.7	93.9 ± 2.5	.054	95.8 ± 1.8	94.7 ± 2.0	.047

Data are presented as mean ± SD unless noted as *n* (%).

%FEV₁ = % of the theoretical value of FEV₁

%FVC = % of the theoretical value of FVC

TLC = total lung capacity

%TLC = % of the theoretical value of TLC

D_{LCO} = diffusing capacity for carbon monoxide

%D_{LCO} = % of the theoretical value of D_{LCO}

Table 4. Sex and Nocturnal Desaturation

	Nocturnal Desaturation		
	No	Yes	P = .02
Sex			
Male (<i>n</i> = 29)	8 (27.6)	21 (72.4)	
Female (<i>n</i> = 28)	16 (57.1)	12 (42.9)	
Total (<i>N</i> = 57)	24 (42.1)	33 (57.9)	

Data are presented as *n* (%).

daily experienced > 80% of sleeping time with an S_{pO₂} < 90% on a daily basis. In the study by Frangolias and Wilcox,²⁰ while 40% of the subjects had nocturnal desaturation, which was related to clinical, radiological, and spirometric variables, the investigators were unable to find a predictive factor for nocturnal desaturation and thus concluded that nocturnal desaturation with %FEV₁ > 65% was infrequent but expected when baseline S_{aO₂} was < 93%. Two other studies suggested that an FEV₁ < 65% predicted could predict hypoxemia during sleep in subjects with CF.^{24,25} Another study in a pediatric population in which pulse oximetry was used correlated S_{pO₂} < 90% at night with FEV₁.²⁶ These results are consistent with ours in that subjects with nocturnal desaturation usually present with an FEV₁ < 65% predicted, along with a P_{aO₂}

≤ 71 mm Hg. We observed nocturnal desaturation in a high percentage of subjects without clinical suspicion. Perhaps this is why more factors that can predict nocturnal desaturation should be studied as a factor in disease progression.

According to Coffey et al,²⁵ hypoxemia in CF occurs more frequently during sleep than during exercise, suggesting that sleep studies may be indicated in patients with CF and hypoxemia during exercise. However, in our study, no 6MWT clinical marker was found to predict nocturnal desaturation. It is likely that the mechanisms of hypoxemia during exercise differ from those during sleep, as demonstrated by the absence of a correlation between measurements in the studies. Another reason for this lack of correlation may be the type of exercise test or submaximal effort by subjects. Different mechanisms, including hypoventilation and changes in ventilation-perfusion relationships, are related to sleep desaturations. On the other hand, exercise-induced desaturations are associated with increased expiratory air-flow resistance and increased dead-space ventilation.^{25,27}

The 6MWT can be viewed as a submaximal exercise, but it is considered to be inaccurate in older subjects with poorer lung function. In the study by Gruet et al,²⁸ subjects with CF had worse outcomes than controls, unlike previous studies such as that performed by Chetta et al.²⁹ Gruet et al²⁸ observed that one third of subjects with CF desatu-

rated during the 6MWT but not during cardiopulmonary exercise testing. These subjects also walked less than the control group. The results of this study suggest that 6MWT desaturation is a better predictor of the maximum cardiopulmonary exercise outcome. However, in the study by Chetta et al,²⁹ CF participants with mild/moderate lung function walked the same distance as control subjects but experienced a significant drop in S_{pO_2} and a greater perception of dyspnea during exercise. They concluded that the 6MWT could be valuable to identify patients who could experience oxygen desaturation and dyspnea during daily activities that require greater effort.

In our study, 6MWT desaturation was associated with FEV_1 % predicted and D_{LCO} . These results were similar to those of other studies, although in previous studies, the distance walked in the 6MWT was the associative factor. Martin et al⁵ found that the 6MWT correlated with FEV_1 , indicating that exercise capacity decreased with increase of air-flow limitation in adults with CF. Other studies, such as that by Okuro et al,³⁰ showed the importance of distance walked in the 6MWT as both a complementary outcome and tool to provide information on exercise response.

The 6MWT may not require enough effort to produce desaturation, which may be why a relationship with nocturnal desaturation was not found. There is another exercise test, the 6-min step test, that requires more effort and may produce more frequent desaturation. It could be a good predictor test and could be validated for patients with CF as it has been for patients with COPD.^{31,32} This is a relatively new area that deserves further study.

Quality of life for patients with CF may be influenced by low oxygen levels in the blood.³³ When exploring desaturation in the 6MWT and the sleep study with the respiratory section of the CFQ-R questionnaire, we found no association. The CFQ-R questionnaire is a useful and easy tool to study quality of life in patients with CF, but there is no research on using the CFQ-R questionnaire in relation to desaturation. The only study of quality of life and home oxygen therapy in subjects with CF showed that, for 12 months, attendance at school and at work remained at 83% for the oxygen-treated group, compared to 20% in those who did not receive oxygen.³³ It was further noted that both sleep quality and duration have a correlation with nighttime S_{pO_2} . However, no relation to mortality, hospitalizations, or disease progression was found.

We believe that the subjects in our study constitute a representative sample of the overall population of adults with CF because they came from the catchment population of our hospital plus various regions in Spain, and they included a broad spectrum of subjects of both sexes and a wide age range.

However, some potential limitations deserve discussion. CF is not a highly prevalent disease, so the study sample

is reduced. This was an adult population in stable condition, so many of them enjoy an optimal respiratory status. In addition, subjects who already had home oxygen therapy were excluded. The potential exclusion of these more serious cases could lead to an underestimation of the true impact of the disease on desaturation in the 6MWT and at night. In the future, we can extend this study with other hospitals to obtain a larger sample size, to confirm the results, and to include participants with greater disease severity.

Conclusion

Desaturation observed during the 6MWT in subjects with CF does not predict desaturation at night. % FEV_1 and D_{LCO} are factors that influence desaturation in the 6MWT. Nocturnal desaturation occurs more often in males with low levels of P_{aO_2} in blood gases. Nocturnal pulse oximetry can be a useful test to detect nocturnal desaturation in patients without clinical suspicion.

REFERENCES

1. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, et al. An overview of international literature from cystic fibrosis registries. Part 4: update 2011. *J Cyst Fibros* 2012;11(6):480-493.
2. Morales P, Sánchez E. Identificación, estructura y expresión del gen CFTR. In: Salcedo A, Gartner S, Girón RM, and García MD, editors *Tratado de Fibrosis Quística*. Madrid: Editorial Justim; 2012:29-40.
3. Cystic Fibrosis Foundation Patient Registry. 2015 Annual Data Report. Bethesda: Maryland; 2016:6-7.
4. Cahalin L, Pappagianopoulos P, Prevost S, Wain J, Ginns L. The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. *Chest* 1995; 108(2):452-459.
5. Martin C, Chapron J, Hubert D, Kanaan R, Honoré I, Paillasseur JL, et al. Prognostic value of six minute walk test in cystic fibrosis adults. *Respir Med* 2013;107(12):1881-1887.
6. Bradley S, Solin P, Wilson J, Johns D, Walters EH, Naughton MT. Hypoxemia and hypercapnia during exercise and sleep in patients with cystic fibrosis. *Chest* 1999;116(3):647-654.
7. De Castro-Silva C, de Bruin VM, Cavalcante AG, Bittencourt LR, de Bruin PF. Nocturnal Hypoxia and Sleep Disturbances in Cystic Fibrosis. *Pediatr Pulmonol* 2009;44(11):1143-1150.
8. Villa MP, Pagani J, Lucidi V, Palamides S, Ronchetti R. Nocturnal oximetry in infants with cystic fibrosis. *Arch Dis Child* 2001;84(1): 50-54.
9. García Hernández G, Martínez Martínez MT. Protocolo de control y seguimiento. In: Salcedo A, Gartner S, Girón RM, and García MD, eds. *Tratado de Fibrosis Quística*. Madrid: Editorial Justim; 2012: 139-147.
10. Uyan ZS, Ozdemir N, Ersu R, Akpınar I, Keskin S, Kadir E. Factors that correlate with sleep oxygenation in children with cystic fibrosis. *Pediatr Pulmonol* 2007;42(8):712-716.
11. Urquhart DS, Montgomery H, Jaffé A. Assessment of hypoxia in children with cystic fibrosis. *Arch Dis Child* 2005;90(11):1138-1143.
12. Gartner S, Cobos N. Cribado neonatal para la fibrosis quística (editorial). *An Pediatr (Barc)* 2009;71(6):481-482.
13. Barrio Gómez de Agüero MI, García Hernández G, Gartner S, Cystic Fibrosis Working Group. Protocolo de diagnóstico y seguimiento de

- los pacientes con fibrosis quística. *An Pediatr (Barc)* 2009;71(3):250-264.
14. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European consensus. *J Cyst Fibros* 2002;1(2):51-75.
 15. Shwachman H, Kulczycki LL. Long term study of 105 patients with cystic fibrosis. *Am J Dis Child* 1958;96:6-10.
 16. Brasfield D, Hicks G, Soong S, Peters J, Tiller R. Evaluation of scoring system of the chest radiograph in cystic fibrosis: a collaborative study. *AJR Am J Roentgenol* 1980;134(6):1195-1198.
 17. Albi G, Rayón-Aledo JC, Caballero P, Rosado P, García-Esparza E. Fibrosis quística en imágenes. Clasificación de Bhalla para la tomografía computarizada en pacientes pediátricos. *Radiología* 2012;54(3):260-268.
 18. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. *Chest* 2005;128(4):2347-2354.
 19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS Statement: Guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002;166(1):111-117.
 20. Frangolias DD, Wilcox PG. Predictability of oxygen desaturation during sleep in patients with cystic fibrosis. *Chest* 2001;119(2):434-441.
 21. Smith DL, Freeman W, Cayton RM, Stableforth DE. Nocturnal hypoxemia in CF: relationship to pulmonary function tests. *Respir Med* 1994;88(7):537-539.
 22. Montgomery M, Wiebicke W, Bibi H, Pagtakhan RD, Pasterkamp H. Home measurement of oxygen saturation during sleep in patients with cystic fibrosis. *Pediatr Pulmonol* 1989;7(1):29-34.
 23. Braggion C, Pradal U, Mastella G. Haemoglobin desaturation during sleep and daytime in patients with cystic fibrosis and severe airway obstruction. *Acta Paediatr* 1992;81(12):1002-1006.
 24. Versteegh FG, Bogaard JM, Raatgever JW, Stam H, Neijens HJ, Kerrebijn KF. Relationship between airway obstruction, desaturation during exercise and nocturnal hypoxemia in cystic fibrosis patients. *Eur Resp J* 1990;3(1):68-73.
 25. Coffey MJ, Fitzgerald MX, McNicholas WT. Comparison of oxygen desaturation during sleep and exercise in patients with cystic fibrosis. *Chest* 1991;100(3):659-662.
 26. Van der Giessen L, Bakker M, Joosten K, Hop W, Tiddens H. Nocturnal oxygen saturation in children with stable cystic fibrosis. *Pediatr Pulmonol* 2012;47(11):1123-1130.
 27. Amann M. Pulmonary system limitations to endurance exercise performance in humans. *Exp Physiol* 2012;97(3):311-318.
 28. Gruet M, Brisswalter J, Mely L, Vallier JM. Use of the peak heart rate reached during six-minute walk test to predict individualized training intensity in patients with cystic fibrosis: validity and reliability. *Arch Phys Med Rehabil* 2010;91(4):602-607.
 29. Chetta A, Pisi G, Zanini A, Foresi A, Grzincich GL, Aiello M, et al. Six-minute walking test in cystic fibrosis adults with mild to moderate lung disease: comparison to healthy subjects. *Respir Med* 2001;95(12):986-991.
 30. Okuro RT, Oliveira Ribeiro MA, Ribeiro JD, Minsky RC, Schivinski CI. Alternative indexes to estimate the functional capacity from the 6-minute walk test in children and adolescents with cystic fibrosis. *Respir Care* 2017;62(3):324-332.
 31. Grosbois JM, Riquier C, Chehere B, Coquart J, Béhal H, Bart F, et al. Six-minute stepper test: a valid clinical exercise tolerance test for COPD patients. *Int J Chron Obstruct Pulmon Dis* 2016;11:657-663.
 32. Coquart JB, Lemaître F, Castres I, Saison S, Bart F, Grosbois JM. Reproducibility and sensitivity of the 6-minute stepper test in patients with COPD. *COPD* 2015;12(5):533-538.
 33. Zinman R, Corey M, Coates AL, Canny GJ, Connolly J, Levison H, et al. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. *J Pediatr* 1989;114(3):368-677.